Entrada Therapeutics, Inc.TRDAEarnings & Financial Report
Nasdaq
TRDA Q3 2025 Key Financial Metrics
Revenue
$1.6M
Gross Profit
N/A
Operating Profit
$-47.1M
Net Profit
$-44.1M
Gross Margin
N/A
Operating Margin
-2915.2%
Net Margin
-2734.4%
YoY Growth
-91.8%
EPS
$-1.06
Financial Flow
Entrada Therapeutics, Inc. Q3 2025 Financial Summary
Entrada Therapeutics, Inc. reported revenue of $1.6M for Q3 2025, with a net profit of $-44.1M (-2734.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $1.6M |
|---|---|
| Net Profit | $-44.1M |
| Gross Margin | N/A |
| Operating Margin | -2915.2% |
| Report Period | Q3 2025 |
Entrada Therapeutics, Inc. Annual Revenue by Year
Entrada Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $210.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $210.8M |
| 2023 | $129.0M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $41.8M | $59.1M | $94.7M | $19.6M | $37.4M | $20.6M | $1.9M | $1.6M |
| YoY Growth | N/A | 134.0% | 421.2% | -55.3% | -10.6% | -65.2% | -97.9% | -91.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $469.2M | $510.8M | $582.0M | $554.6M | $526.3M | $486.5M | $448.8M | $412.9M |
| Liabilities | $226.8M | $241.5M | $152.0M | $132.1M | $97.6M | $69.2M | $69.3M | $72.2M |
| Equity | $242.4M | $269.4M | $429.9M | $422.4M | $428.7M | $417.3M | $379.5M | $340.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.0M | $-25.5M | $39.8M | $-24.3M | $-31.6M | $-38.5M | $-29.5M | $-28.3M |